胃癌免疫治疗的研究现状及进展

doi:10.11904/j.issn.1002-3070.2023.04.012

摘要/Abstract

摘要： 目的胃癌作为一种具有高侵袭性和异质性的恶性肿瘤,是一个棘手的全球性健康问题,且目前胃癌的常规化疗存在耐药、易复发、不良反应严重等局限性。近年来人们对肿瘤相关基因及肿瘤发生发展机制进行了深入研究,研发出各类新型药物用于治疗胃癌,包括靶向药物、免疫治疗药等,并制定了不同的联合治疗策略,大大提高了胃癌患者的疗效。本文将围绕近几年胃癌免疫治疗的研究现状及进展进行综述。

关键词: 胃癌, 免疫治疗, 靶向药物

Abstract: Gastric cancer, as a highly invasive and heterogeneous malignant tumor, is a thorny global health issue. Currently, conventional chemotherapy for gastric cancer has limitations such as drug resistance, susceptibility to recurrence, and severe adverse reaction. In recent years, many researchers have conducted many studies in-depth on tumors related to genes and the mechanisms of tumor occurrence and development, developed kinds of new drugs for gastric cancer treatment, including targeted drugs, immunotherapy drugs, etc., and formulated different combination therapy strategies, which greatly improved the efficacy of gastric cancer patients. This article will review the research status and progress of immunotherapy for gastric cancer in recent years.

Key words: Gastric cancer, Immunotherapy, Targeted drugs

中图分类号:

R979.1

李娟, 刘家仁. 胃癌免疫治疗的研究现状及进展[J]. 实用肿瘤学杂志, 2023, 37(4): 372-376.

LI Juan, LIU Jiaren. The current research status and progress of immunotherapy for gastric cancer[J]. Journal of Practical Oncology, 2023, 37(4): 372-376.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.04.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I4/372

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Abbott M,Ustoyev Y.Cancer and the immune system:the history and background of immunotherapy[J].Semin Oncol Nurs,2019,35(5):150923.
3 Park R,Williamson S,Kasi A,et al.Immune therapeutics in the treatment of advanced gastric and esophageal cancer[J].Anticancer Res,2018,38(10):5569-5580.
4 Muro K,Chung HC,Shankaran V,et al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer(KEYNOTE-012):a multicentre,open-label,phase 1b trial[J].Lancet Oncol,2016,17(6):717-726.
5 Fuchs CS,Doi T,Jang RW,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncol,2018,4(5):e180013.
6 Kang YK,Boku N,Satoh T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.
7 Boku N,Satoh T,Ryu MH,et al.Nivolumab in previously treated advanced gastric cancer(ATTRACTION-2):3-year update and outcome of treatment beyond progression with nivolumab[J].Gastric Cancer,2021,24(4):946-958.
8 Moehler M,Dvorkin M,Boku N,et al.Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers:results from javelin gastric 100[J].J Clin Oncol,2021,39(9):966-977.
9 Hosseini A,Gharibi T,Marofi F,et al.CTLA-4:From mechanism to autoimmune therapy[J].Int Immunopharmacol,2020,80:106221.
10 Ralph C,Elkord E,Burt DJ,et al.Modulation of lymphocyte regulation for cancer therapy:a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma[J].Clin Cancer Res,2010,16(5):1662-1672.
11 Sun JM,Shen L,Shah MA,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590):a randomised,placebo-controlled,phase 3 study[J].Lancet,2021,398(10302):759-771.
12 Shitara K,Van Cutsem E,Bang YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line,advanced gastric cancer:the KEYNOTE-062 phase 3 randomized clinical trial[J].JAMA Oncol,2020,6(10):1571-1580.
13 Janjigian YY,Shitara K,Moehler M,et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma(CheckMate 649):a randomised,open-label,phase 3 trial[J].Lancet,2021,398(10294):27-40.
14 LIU T,BAI Y,LIN X,et al.First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric,gastroesophageal junction and esophageal adenocarcinoma:CheckMate 649 Chinese subgroup analysis[J].Int J Cancer,2023,152(4):749-760.
15 JIANG H,ZHENG Y,QIAN J,et al.Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial[J].BMC Cancer,2020,20(1):760.
16 XU J,JIANG H,PAN Y,et al.LBA53 Sintilimab plus chemotherapy(chemo)versus chemo as first-line treatment for advanced gastric or gastroesophageal junction(G/GEJ)adenocarcinoma(ORIENT-16):First results of a randomized,double-blind,phase III study[J].Annals of Oncology,2021,32:S1331.
17 WANG F,WEI XL,WANG FH,et al.Safety,efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab,a PD-1 antibody in phase Ib/II clinical trial NCT02915432[J].Ann Oncol,2019,30(9):1479-1486.
18 Tabernero J,Bang YJ,Van Cutsem E,et al.KEYNOTE-859:a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma[J].Future Oncol,2021,17(22):2847-2855.
19 Rotte A.Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J].J Exp Clin Cancer Res,2019,38(1):255.
20 Keam S J.Cadonilimab:First Approval[J].Drugs,2022,82(12):1333-1339.
21 Janjigian YY,Bendell J,Calvo E,et al.CheckMate-032 study:efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer[J].J Clin Oncol,2018,36(28):2836-2844.
22 Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
23 Janjigian YY,Kawazoe A,Yaez P,et al.The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J].Nature,2021,600(7890):727-730.
24 Shitara K,Iwata H,Takahashi S,et al.Trastuzumab deruxtecan(DS-8201a)in patients with advanced HER2-positive gastric cancer:a dose-expansion,phase 1 study[J].Lancet Oncol,2019,20(6):827-836.
25 Janjigian YY,Oh D-Y,Rha SY,et al.Dose-escalation and dose-expansion study of trastuzumab deruxtecan(T-DXd)monotherapy and combinations in patients(pts)with advanced/metastatic HER2+ gastric cancer(GC)/gastroesophageal junction adenocarcinoma(GEJA):DESTINY-Gastric03[J].J Clin Oncol,2022,40(4_suppl):295.
26 Fukuoka S,Hara H,Takahashi N,et al.Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer:an open-label,dose-escalation,and dose-expansion phase Ib trial(REGONIVO,EPOC1603)[J].J Clin Oncol,2020,38(18):2053-2061.
27 Nakajima TE,Kadowaki S,Minashi K,et al.Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer[J].Clin Cancer Res,2021,27(4):1029-1036.
28 Geisler AN,Phillips GS,Barrios DM,et al.Immune checkpoint inhibitor-related dermatologic adverse events[J].J Am Acad Dermatol,2020,83(5):1255-1268.
29 CHANG X,GE X,ZHANG Y,et al.The current management and biomarkers of immunotherapy in advanced gastric cancer[J].Medicine(Baltimore),2022,101(21):e29304.
30 Alcantara M,Du Rusquec P,Romano E.Current clinical evidence and potential solutions to increase benefit of CAR T-Cell therapy for patients with solid tumors[J].Oncoimmunology,2020,9(1):1777064.
31 TAO K,HE M,TAO F,et al.Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment[J].Cancer Chemother Pharmacol,2018,82(5):815-827.
32 LV J,ZHAO R,WU D,et al.Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer[J].J Hematol Oncol,2019,12(1):18.
33 QI C,GONG J,LI J,et al.Claudin18.2-specific CAR T cells in gastrointestinal cancers:phase 1 trial interim results[J].Nat Med,2022,28(6):1189-1198.
34 HE J,XIONG X,YANG H,et al.Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response[J].Cell Res,2022,32(6):530-542.
35 Fujiwara S,Wada H,Kawada J,et al.NY-ESO-1 antibody as a novel tumour marker of gastric cancer[J].Br J Cancer,2013,108(5):1119-1125.
36 Ishikawa H,Imano M,Shiraishi O,et al.Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer[J].Gastric Cancer,2014,17(1):173-180.
37 LIU Q,CHU Y,SHAO J,et al.Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high-risk gastric/gastroesophageal junction cancer[J].Adv Sci(Weinh),2022,10(1):e2203298.

[1]	付鑫雅, 胡灵丹, 张志坚, 马秀梅. HPA通过上调MCP-1/CCR2促进胃癌发生侵袭和转移[J]. 实用肿瘤学杂志, 2023, 37(4): 329-336.
[2]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[3]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[4]	韩焱崧, 任明华. 前列腺癌骨转移机制和骨靶向药物研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 252-256.
[5]	周海茸, 王巍巍, 王琛琛, 洪忻. 2007—2019年南京市胃癌死亡率及早死寿命损失年变化趋势分析[J]. 实用肿瘤学杂志, 2023, 37(2): 102-106.
[6]	李路桥, 邹征云. 恶性黑色素瘤免疫治疗超进展研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 144-148.
[7]	明成, 武云. Wnt信号通路及其抑制剂在胃癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 190-194.
[8]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[9]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[10]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[11]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[12]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[13]	程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.
[14]	徐伟, 刘海鹏, 汪文杰, 王舟, 李元元, 沈亦敏, 陈晓. 胃癌术后胆囊结石形成的危险因素及预防措施的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 561-565.
[15]	李浩, 张鹤骞, 高佳宁, 滕立臣. 立体定向体部放疗联合靶向药物治疗转移性肾癌的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 580-584.